ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Design Therapeutics (DSGN)
Design Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$10.63▲ +2.80%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
47%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Design Therapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Design Therapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Design Therapeutics a 47% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $9.38 and $11.76; in 9 out of 10, between $7.68 and $14.36. Estimated annual volatility is 62%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $772M
- 52-week high
- $17.25
- 52-week low
- $6.16
- Revenue (12 months)
- $0.0M
- Return on equity
- -34.1%
- Free cash flow (12 months)
- $-32.4M
- Beta
- 1.66
What this means
ATLAS does not publish a fair value for DSGN right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks DSGN has traded between $6.16 and $17.25. Today it is 38.4% below that high and 73% above its low.
Its beta is 1.66: it tends to move more than the market, both up and down.
About the company
Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing GeneTAC small-molecule therapies for serious genetic diseases.
Want to see everything about Design Therapeutics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Design Therapeutics do?
Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing GeneTAC small-molecule therapies for serious genetic diseases.
What is the chance DSGN goes up next month?
47%: close to a coin flip. In half of the simulated outcomes, DSGN ends the month between $9.38 and $11.76.
How big is Design Therapeutics and what is its P/E ratio?
Design Therapeutics's market capitalization is $772M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is DSGN?
ATLAS estimates annual volatility at 62%. In a typical month, half of the outcomes end between $9.38 and $11.76.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer